Progen Pharmaceuticals
Progen Pharmaceuticals

Epigenetics


Epigenetics series

Epigenetics is a new area of gene expression research focused on the modulation of the expression of genes, and in particular those associated with cancer. This process is mediated by enzymes such as Histones Deacethylases (HDACs) and Lysine Specific Demethylase (LSD1). Many of Progen's polyamine platform products have demonstrated that they can inhibit HDAC and LSD1, leading to re-expression of 'silenced' tumor suppressor genes. This in turn has been demonstrated to lead to inhibition of tumor growth in a number of pre-clinical studies. Progen is working actively to determine which of these product series has the best commercial profile for further development and is moving these assets towards clinical development.

Home Our Company Our Technology Our Pipeline Investor Centre